drugset

drugset / Trial / NCT04844450

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

NCT04844450 ↗

Phase 1 Completed 55 enrolled Janssen Research & Development, LLC

RandomizedSequentialDouble-blindTreatment

Summary

The purpose of the study is to assess the safety and tolerability of single and multiple subcutaneous (SC) doses of JNJ-75220795.

Timeline

Start: 2021-04-29
Primary completion: 2023-03-31
Completion: 2023-03-31

Publications

Wang C, Guo P, Liu X, Xu X, Zou L, Meng S, Guo Q, Wen Q, Yang C. Association Between PNPLA3 Inhibition and Gout: A Drug Target Mendelian Randomization Study. Int J Endocrinol. 2025 Aug 20;2025:6664846. doi: 10.1155/ije/6664846. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-75220795	Unknown	—	Subcutaneous

Indications